Phase 2 N=27 Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
Soft Tissue Sarcoma · Recurrent Soft Tissue Sarcoma
Primary: Rate of Complete Tumor Necrosis — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
Healthy
Primary: Change in C-terminal Telopeptide of Type I Collagen [CTX] — -4.1; 13.7; -7.7 percent change — p=0.611
Phase 2 N=620 Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
Plasmodium Falciparum
Primary: Time to First PCR-detectable Malaria Infection During the Active Detection of Infection (ADI) Phase in Groups 1 and 4 — 1.01; 1.49 Events per person year at risk — p=0.009
Phase 2 N=10 A Healthy Volunteer Trial Investigating MR-enterography Image Quality of Lumentin® 44
Healthy
Primary: Visual Evaluation of MRE Images - Motility — 0; 6; 4; 0 Participants
Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
Phase 2 N=6 Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
B-Cell Prolymphocytic Leukemia · Chronic Lymphocytic Leukemia · Peripheral T-Cell Lymphoma
Primary: Cytomegalovirus (CMV) Reactivation
Phase 2 N=46 Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glucose Area Under the Plasma Concentration Versus Time Curve From Zero to 4 Hours Post-dose AUC(0-4) — -190.0296; -182.7172; -57.0768; -40.6842…
Phase 2 N=324 A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
Borderline Personality Disorder
Primary: Change From Baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score — -7.27; -6.25 score on a scale — p=0.2430
Phase 2 N=64 Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
B-Thalassemia
Primary: Percentage of Non-transfusion Dependent (NTD) Participants With a Hemoglobin Increase of ≥1.5 g/dL From Baseline for ≥14 Days — 0.0; 0.0; 0.0; 66.7 Percentage of…
Phase 2 N=8 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
CAH - Congenital Adrenal Hyperplasia
Primary: Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average) — -69.48 percent change
Phase 2 N=29 Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Liposarcoma · Metastatic Liposarcoma
Primary: Number of Participants Who Were Progression Free — 12 Participants
Phase 2 N=51 Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
β-Thalassemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 50 Participants
Phase 2 N=57 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
Lupus Nephritis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 33; 18; 6; 3 Participants
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
Phase 2 N=44 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
Leukemia, Myelomonocytic, Chronic
Primary: Objective Response Rate (ORR) — 0; 0; 0; 0 Participants